Zoetis Inc.

Zoetis makes vaccines and drugs for livestock and companion animals by holding USDA biologics licences tied to specific products at specific manufacturing facilities — a cattle vaccine line and a swine vaccine line cannot share the same equipment because cross-species contamination causes adverse immune reactions, so each species requires its own segregated, licensed production line. The clinical data those licences rest on must come from actual farms and veterinary schools, where seasonal breeding cycles and mixed-species pathogen exposure produce the field-condition evidence that USDA and FDA require, which means a competitor cannot replicate that evidence in a laboratory and must run the same years-long sequential trials at the same kinds of sites. Once a line is licensed and a formula approved, scaling output on that line is relatively cheap — but adding a new species or disease indication resets the whole clock, so the number of new products the company can bring to market each year is capped by biological trial timelines, not by money or manufacturing space. The whole structure depends on veterinary schools and working livestock operations remaining available as trial sites, because if farm consolidation or academic policy changes cut off access to those environments, the pipeline of new approvals stops regardless of how much capital the company has available.